BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock
$8,77
Fiyat · May 20, 2026
Temel veriler itibarıyla May 12, 2026
52 Haftlık Aralık
$8–$15
16% of range
Analist Derecelendirmesi
BUY
15 analysts
Fiyat Hedefi
$25
+186% upside
P/E (TTM)
-2.9
ROE
-146.2%
Net Kâr Marjı
—
BBOT Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$8.77
Piyasa Değeri
$1.00B
P/E (TTM)
-2.9
EPS (TTM)
$-4.30
Gelir (TTM)
—
Temettü Verimi
—
ROE
-146.2%
D/E Borç/Özsermaye
0.0
52 Haftlık Aralık
$8 – $15
BBOT Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
—
Hisse Başına Kâr
$-4.30
2024-12-31
→
2025-12-31
Serbest Nakit Akışı
$-114M
2025-12-31
→
2025-12-31
Marjlar
—
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
BBOT
Akran Ortalaması
P/E (TTM)
-2.9
139.1
P/B (F/D)
2.4
2.4
EV / EBITDA
-4.0
—
Price / FCF (Fiyat / Serbest Nakit Akışı)
-8.7
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
BBOT
Akran Ortalaması
ROA
-43.8%
-36.3%
ROE
-146.2%
-51.4%
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
BBOT
Akran Ortalaması
Debt / Equity (Borç / Öz Sermaye)
0.0
—
Current Ratio (Cari Oran)
12.3
6.1
Quick Ratio (Cari Oran)
12.1
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
BBOT
Akran Ortalaması
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
BBOT
Akran Ortalaması
BBOT Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
15 analist
- Güçlü Al 6 40,0%
- Al 8 53,3%
- Tut 1 6,7%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
9 analist · 2026-05-16
Medyan
$23.00
Ortalama
$25.11
← Tüm hedeflerin altında
$8.77
Düşük
$18.00
Yüksek
$41.00
Medyan hedef
$23.00
+162,3%
Ortalama hedef
$25.11
+186,3%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-0.20%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 31 Mart 2026 | $-0.53 | $-0.54 | 0.01% |
| 31 Aralık 2025 | $-0.49 | $-0.53 | 0.04% |
| 30 Eylül 2025 | $-1.03 | $-0.40 | -0.63% |
Eş Karşılaştırması Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| BBOT | $1.00B | -2.9 | — | — | -146.2% | — |
| XNCR | $1.10B | -12.3 | 13.7% | -73.2% | -14.0% | — |
| VOR | $506M | -0.2 | — | — | 83.4% | — |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | — |
| SPRY | $1.16B | -6.7 | -5.5% | -203.3% | -111.8% | — |
| DSGN | $567M | -7.7 | — | — | -32.8% | — |
| ALLO | $314M | -1.6 | -76.8% | — | -59.9% | — |
| SLDB | $445M | -2.8 | — | — | -79.5% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 13
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $121M | $73M | · | |
| SG&A Expense | $25M | $8M | $41.7K | |
| Operating Expenses | $146M | $81M | · | |
| Operating Income | $-146M | $-81M | $-41.7K | |
| Interest Income | $11M | $6M | · | |
| Other Non-op | $-35.0K | $0 | · | |
| Income Tax | $0 | $0 | · | |
| Net Income | $-134M | $-74M | $-41.7K | |
| EPS (Basic) | $-4.30 | $-5756.41 | · | |
| EPS (Diluted) | $-4.30 | $-5756.41 | · | |
| Shares (Basic) | 31,144,775 | 12,903 | · | |
| Shares (Diluted) | 31,144,775 | 12,903 | · | |
| EBITDA | $-146M | $-584.4K | · |
Bilanço 21
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $374M | $31M | $0 | |
| Short-term Investments | $52M | $125M | · | |
| Prepaid Expense | $7M | $3M | · | |
| Current Assets | $432M | $159M | · | |
| PP&E (Net) | $956.0K | $490.0K | · | |
| Other Non-current Assets | $13M | $5M | · | |
| Total Assets | $448M | $164M | $332.9K | |
| Accounts Payable | $1M | $3M | · | |
| Accrued Liabilities | · | $119.7K | $15.0K | |
| Short-term Debt | $534.0K | $483.0K | $70.1K | |
| Current Liabilities | $35M | $20M | $396.5K | |
| Capital Leases | $2M | $0 | · | |
| Total Liabilities | $37M | $20M | $396.5K | |
| Total Debt | $534.0K | · | · | |
| Common Stock | $8.0K | $0 | · | |
| Paid-in Capital | $768M | $44M | $24.5K | |
| Retained Earnings | $-357M | $-223M | $-88.6K | |
| AOCI | $16.0K | $348.0K | · | |
| Stockholders' Equity | $411M | $-179M | $-116M | |
| Liabilities + Equity | $448M | $164M | $332.9K | |
| Shares Outstanding | 79,991,768 | 28,415 | · |
Nakit Akışı 9
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | · | |
| Deferred Tax | $0 | $0 | · | |
| Operating Cash Flow | $-114M | $-55M | · | |
| CapEx | $606.0K | $49.0K | · | |
| Investing Cash Flow | $73M | $-121M | · | |
| Stock Issued | $112M | · | · | |
| Net Stock Activity | $112M | · | · | |
| Financing Cash Flow | $383M | $206M | · | |
| Free Cash Flow | $-114M | · | · |
Kârlılık 2
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -43.8% | 7.8% | · | |
| ROE | -146.2% | -9.3% | · |
Likidite ve Solventlik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 12.3 | 10.4 | · | |
| Quick Ratio | 12.1 | 9.1 | · | |
| Debt / Equity | 0.0 | · | · |
Değerleme (TTM) 11
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-134M | $-74M | · | |
| Market Cap | $1.00B | · | · | |
| Enterprise Value | $577M | · | · | |
| P/E | -2.9 | -0.0 | · | |
| P/B | 2.4 | · | · | |
| P / Tangible Book | 2.4 | · | · | |
| P / Cash Flow | -8.8 | · | · | |
| P / FCF | -8.7 | · | · | |
| EV / EBITDA | -4.0 | · | · | |
| EV / FCF | -5.0 | · | · | |
| Earnings Yield | -34.4% | -54823.0% | · |
Gelir Tablosu 13
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $40M | $38M | $35M | · | $21M | $20M | $18M | · | · | |
| SG&A Expense | $6M | $7M | $14M | $1M | $3M | $6M | $2M | $152.3K | $66.7K | |
| Operating Expenses | $46M | $43M | $49M | · | $23M | $22M | $20M | · | · | |
| Operating Income | $-46M | $-93M | $-49M | $-1M | $-23M | $-61M | $-20M | $-152.3K | $-66.7K | |
| Interest Income | $4M | $4M | $3M | $2M | $2M | $255.2K | $2M | $2M | $1M | |
| Other Non-op | $-94.0K | $-4M | $-30.0K | $2M | $-2.0K | $-4M | $0 | $2M | $1M | |
| Income Tax | · | $0 | $0 | $0 | $0 | $0 | $0 | · | · | |
| Net Income | $-42M | $-39M | $-45M | $-28M | $-22M | $-20M | $-17M | $-22M | $-15M | |
| EPS (Basic) | $-526.11 | $2.19 | $-1.03 | · | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| EPS (Diluted) | $-526.11 | $2.19 | $-1.03 | · | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| Shares (Basic) | 80,032 | 16,459,785 | 43,491,085 | · | 406,723 | 1,814 | 11,089 | · | · | |
| Shares (Diluted) | 80,032 | 16,459,785 | 43,491,085 | · | 406,723 | 1,814 | 11,089 | · | · | |
| EBITDA | $-46M | · | $-49M | $-1M | $-2M | · | $-146.9K | $-152.3K | $-66.7K |
Bilanço 21
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $374M | $409M | $664.2K | $963.1K | $31M | $2M | $2M | $2M | |
| Short-term Investments | $200M | $52M | $60M | · | · | $125M | · | · | · | |
| Prepaid Expense | $14M | $7M | $7M | $62.5K | · | $3M | · | $11.3K | $16.3K | |
| Current Assets | $267M | $432M | $476M | $876.8K | $1M | $159M | $2M | $2M | $2M | |
| PP&E (Net) | $938.0K | $956.0K | $827.0K | · | · | $490.0K | · | · | · | |
| Other Non-current Assets | $11M | $13M | $5M | · | · | $5M | · | · | · | |
| Total Assets | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Accounts Payable | $12M | $1M | $4M | $3M | · | $3M | · | · | · | |
| Accrued Liabilities | · | · | · | · | $2M | · | $126.7K | $79.1K | $23.3K | |
| Short-term Debt | $716.0K | $534.0K | $691.0K | · | · | $483.0K | · | · | · | |
| Current Liabilities | $43M | $35M | $36M | $3M | $2M | $20M | $126.7K | $79.1K | $23.3K | |
| Capital Leases | $2M | $2M | $2M | · | · | $0 | · | · | · | |
| Total Liabilities | $45M | $37M | $38M | $8M | $7M | $20M | $6M | $6M | $6M | |
| Total Debt | $716.0K | · | $691.0K | · | · | · | · | · | · | |
| Common Stock | $8.0K | $8.0K | $8.0K | · | · | $0 | · | · | $51 | |
| Paid-in Capital | $772M | $768M | $764M | · | · | $44M | · | · | · | |
| Retained Earnings | $-399M | $-357M | $-318M | $-7M | $-6M | $-223M | $-4M | $-3M | $-3M | |
| AOCI | $-981.0K | $16.0K | $36.0K | · | · | $348.0K | · | · | · | |
| Stockholders' Equity | $372M | $411M | $447M | $-7M | $-6M | $-179M | $-4M | $-3M | $-3M | |
| Liabilities + Equity | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Shares Outstanding | 80,088,931 | 79,991,768 | 79,196,710 | · | · | 28,415 | · | · | · |
Nakit Akışı 8
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $3M | $3M | $36.0K | $627.0K | $4M | $77.4K | $77.4K | $39.4K | |
| Operating Cash Flow | $-36M | $-42M | $-71M | $-298.9K | $-20M | $-15M | $-39M | $-29.1K | $-618.0K | |
| CapEx | $24.0K | $73.0K | · | · | $162.0K | $10.0K | · | · | · | |
| Investing Cash Flow | $-285M | $8M | · | · | $15M | $26M | $38M | $0 | $-184M | |
| Stock Issued | $112M | $-9M | · | · | · | · | · | · | · | |
| Net Stock Activity | $112M | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $295.0K | $-586.0K | · | · | $-404.0K | $52.0K | $20M | $0 | $186M | |
| Free Cash Flow | $-36M | · | · | · | · | · | · | · | · |
Kârlılık 2
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -13.7% | · | -13.2% | 0.47% | -0.25% | · | 2.4% | 2.3% | 1.2% | |
| ROE | -23.0% | · | -20.2% | -17.2% | 10.4% | · | -132.7% | -131.2% | -68.3% |
Likidite ve Solventlik 3
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.2 | · | 13.3 | 0.3 | 0.7 | · | 16.1 | 26.2 | 90.4 | |
| Quick Ratio | 5.8 | · | 13.1 | 0.3 | 0.5 | · | 14.1 | 22.9 | 79.0 | |
| Debt / Equity | 0.0 | · | 0.0 | · | · | · | · | · | · |
Değerleme (TTM) 9
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-137M | · | $-113M | $-90M | $-77M | · | · | · | · | |
| Market Cap | $717M | · | $917M | · | · | · | · | · | · | |
| Enterprise Value | $465M | · | $450M | · | · | · | · | · | · | |
| P/B | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Tangible Book | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Cash Flow | -20.0 | · | · | · | · | · | · | · | · | |
| P / FCF | -19.9 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -10.1 | · | -9.1 | · | · | · | · | · | · | |
| EV / FCF | -12.9 | · | · | · | · | · | · | · | · |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Net Gelir | $-134M | $-74M | $-41.7K |
| Seyreltilmiş Hisse Başı Kâr | $-4.30 | $-5756.41 | — |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Borç / Öz Sermaye | 0.0 | — | — |
| Cari Oran | 12.3 | 10.4 | — |
| Cari Oran | 12.1 | 9.1 | — |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Serbest Nakit Akışı | $-114M | — | — |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.